leisure time -WSS

leisure time

author：focus 2025-09-30 20:05:38 - browse：91423

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： 10 million people disenrolled from Medicaid over past six months

entertainment

WSS

Abortion clinic in Cancun will cater to Americans

MoonLake credibility takes another hit with mid

Lung cancer screening guidelines updated for cigarette smokers

Diversify hospital leadership teams to protect BIPOC patient health

More doctors should go into startup world

Life sciences investors close nearly $6 billion in new funds

hotspot

leisure time

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Will General Catalyst be the first of many hospital takeovers?

Medicare details structure of new drug price negotiation program

Senate panel clears PBM, hopsital reforms

Walensky prepares to leave CDC — and Congress — behind

After Sarepta trial failure, Duchenne families brace for more debate

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Coloradans with cystic fibrosis could lose access to Trikafta

DIEP, the 'gold standard' of breast reconstruction, is under threat

Ambulance rides for just $100? Advisers want major billing fixes

knowledge

MoonLake credibility takes another hit with mid

Biotech incubator Curie.Bio graduates its first startup

Key Senate panel to consider PBM, drug pricing reform package

UCSF medical school apologizes for unethical prisoner experiments

Sanofi CEO defends move to abandon profit guidance, boost research

DeepMind touts AlphaFold's new skills as protein folding AI models face off

leisure time

entertainment

leisure time

leisure time